Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Johnson & Johnson (JNJ) shares are in focus after two pipeline updates: a Phase 2b win for nipocalimab in systemic lupus ...
Merck stock surges 30% on strong fundamentals, regulatory catalysts, and attractive valuation. See why I rate the MRK stock a ...
Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s ...
Angels, Brewers, Cardinals among 9 MLB teams to cancel broadcast deal After 79 years and 7 months, Chick-fil-A just made a ...
WisdomTree U.S. LargeCap Dividend Fund ETF (DLN) offers a compelling alternative to SCHD for dividend investors seeking ...
A former dealmaker at Lazard Ltd., one of Wall Street’s most prominent investment banks, is accused by US authorities of feeding tips on health-care deals to a friend’s network of insider traders, who ...
Diversification is key to successful long-term investing. In other words, don't put all your eggs in one basket.
Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
24/7 Wall St. on MSN
Is Fidelity’s health care ETF a good buy right now?
Quick Read FHLC charges just 0.084% in fees but carries 13% concentration in Eli Lilly. The fund gained 17.9% over one year ...
Diversification is key to successful long-term investing. In other words, don't put all your eggs in one basket.
J&J shares positive long-term results of Rybrevant study for RAS/BRAF wild-type metastatic colorectal cancer at ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback